Home ETF List About

Portfolio Holdings Detail for ISIN IE00BFNM3H51
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerSDUS(USD) LSE
ETF TickerSLUS(EUR) F
ETF TickerSDUS.LS(USD) CXE
ETF TickerSLUS.DE(EUR) CXE
ETF TickerSDUS.L(GBP) LSE

Holdings detail for ALNY

Stock NameAlnylam Pharmaceuticals Inc
TickerALNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS02043Q1076
LEI529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI USA ESG Screened UCITS ETF USD (Dist) ALNY holdings

DateNumber of ALNY Shares HeldBase Market Value of ALNY SharesLocal Market Value of ALNY SharesChange in ALNY Shares HeldChange in ALNY Base ValueCurrent Price per ALNY Share HeldPrevious Price per ALNY Share Held
2025-11-11 (Tuesday)41,191USD 18,616,272ALNY holding increased by 422207USD 18,616,2720USD 422,207 USD 451.95 USD 441.7
2025-11-10 (Monday)41,191ALNY holding increased by 160USD 18,194,065ALNY holding increased by 29641USD 18,194,065160USD 29,641 USD 441.7 USD 442.7
2025-11-07 (Friday)41,031ALNY holding decreased by -16USD 18,164,424ALNY holding increased by 83631USD 18,164,424-16USD 83,631 USD 442.7 USD 440.49
2025-11-06 (Thursday)41,047ALNY holding decreased by -32USD 18,080,793ALNY holding increased by 229503USD 18,080,793-32USD 229,503 USD 440.49 USD 434.56
2025-11-05 (Wednesday)41,079ALNY holding increased by 104USD 17,851,290ALNY holding increased by 499607USD 17,851,290104USD 499,607 USD 434.56 USD 423.47
2025-11-04 (Tuesday)40,975ALNY holding increased by 128USD 17,351,683ALNY holding decreased by -378774USD 17,351,683128USD -378,774 USD 423.47 USD 434.07
2025-11-03 (Monday)40,847ALNY holding decreased by -64USD 17,730,457ALNY holding decreased by -926595USD 17,730,457-64USD -926,595 USD 434.07 USD 456.04
2025-10-31 (Friday)40,911USD 18,657,052ALNY holding increased by 265103USD 18,657,0520USD 265,103 USD 456.04 USD 449.56
2025-10-30 (Thursday)40,911ALNY holding increased by 400USD 18,391,949ALNY holding decreased by -1117743USD 18,391,949400USD -1,117,743 USD 449.56 USD 481.59
2025-10-29 (Wednesday)40,511ALNY holding increased by 400USD 19,509,692ALNY holding increased by 420466USD 19,509,692400USD 420,466 USD 481.59 USD 475.91
2025-10-28 (Tuesday)40,111ALNY holding increased by 40USD 19,089,226ALNY holding decreased by -87953USD 19,089,22640USD -87,953 USD 475.91 USD 478.58
2025-10-27 (Monday)40,071ALNY holding increased by 24USD 19,177,179ALNY holding increased by 618198USD 19,177,17924USD 618,198 USD 478.58 USD 463.43
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BFNM3H51

Show aggregate share trades of ALNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY160449.680440.930 441.805USD 70,689 305.44
2025-11-07SELL-16443.587430.835 432.110USD -6,914 304.77 Loss of -2,037 on sale
2025-11-06SELL-32445.490429.000 430.649USD -13,781 304.10 Loss of -4,049 on sale
2025-11-05BUY104438.530417.000 419.153USD 43,592 303.46
2025-11-04BUY128431.500421.830 422.797USD 54,118 302.87
2025-11-03SELL-64457.260429.615 432.379USD -27,672 302.21 Loss of -8,331 on sale
2025-10-30BUY400471.980436.512 440.059USD 176,023 300.70
2025-10-29BUY400481.590482.730 482.616USD 193,046 299.79
2025-10-28BUY40475.910484.610 483.740USD 19,350 298.89
2025-10-27BUY24478.580485.360 484.682USD 11,632 297.98
2025-10-24BUY16463.430469.290 468.704USD 7,499 297.13
2025-10-21BUY24474.000490.050 488.445USD 11,723 294.46
2025-10-20BUY88491.220495.550 495.117USD 43,570 293.43
2025-10-16BUY80481.070488.390 487.658USD 39,013 291.45
2025-10-15BUY96470.270485.280 483.779USD 46,443 290.49
2025-10-02BUY64460.990461.530 461.476USD 29,534 288.62
2025-10-01BUY96460.650467.420 466.743USD 44,807 287.69
2025-09-30BUY584456.000459.300 458.970USD 268,038 286.77
2025-09-29BUY152447.490451.630 451.216USD 68,585 285.89
2025-09-26BUY344446.400453.050 452.385USD 155,620 285.01
2025-09-25BUY24449.580459.000 458.058USD 10,993 284.10
2025-09-24BUY456458.370462.690 462.258USD 210,790 283.13
2025-09-18BUY96452.170456.940 456.463USD 43,820 282.19
2025-09-17BUY120451.730463.880 462.665USD 55,520 281.24
2025-09-16BUY192461.240467.280 466.676USD 89,602 280.22
2025-08-15BUY16448.910449.520 449.459USD 7,191 278.25
2025-08-13BUY8432.520438.230 437.659USD 3,501 277.36
2025-08-08BUY72438.930439.360 439.317USD 31,631 276.43
2025-08-06BUY152428.140428.690 428.635USD 65,153 274.61
2025-07-31BUY40392.240402.430 401.411USD 16,056 273.06
2025-07-29BUY160330.550331.060 331.009USD 52,961 272.32
2025-07-11BUY64314.940321.120 320.502USD 20,512 272.06
2025-07-10BUY72322.640324.820 324.602USD 23,371 271.75
2025-07-09BUY72320.870322.680 322.499USD 23,220 271.45
2025-07-07SELL-48324.130328.240 327.829USD -15,736 270.84 Loss of -2,735 on sale
2025-07-02SELL-200329.770330.000 329.977USD -65,995 269.71 Loss of -12,054 on sale
2025-06-27BUY24322.830323.200 323.163USD 7,756 269.01
2025-06-26BUY24318.250325.000 324.325USD 7,784 268.69
2025-06-24SELL-112325.000326.030 325.927USD -36,504 267.98 Loss of -6,490 on sale
2025-06-18BUY64312.320317.540 317.018USD 20,289 266.81
2025-06-17BUY24308.710309.060 309.025USD 7,417 266.53
2025-06-16SELL-32308.780309.630 309.545USD -9,905 266.24 Loss of -1,386 on sale
2025-06-12SELL-40304.670307.480 307.199USD -12,288 265.98 Loss of -1,649 on sale
2025-06-11BUY88298.580303.850 303.323USD 26,692 265.76
2025-06-06BUY24300.830310.220 309.281USD 7,423 264.99
2025-06-05BUY112308.000308.530 308.477USD 34,549 264.69
2025-06-04BUY16305.310308.930 308.568USD 4,937 264.40
2025-06-03SELL-8303.770307.850 307.442USD -2,460 264.12 Loss of -347 on sale
2025-05-30SELL-976304.560306.000 305.856USD -298,515 263.52 Loss of -41,319 on sale
2025-05-29BUY24292.900293.220 293.188USD 7,037 263.31
2025-05-27BUY136290.100295.440 294.906USD 40,107 262.94
2025-05-23BUY120289.960291.220 291.094USD 34,931 262.54
2025-05-22BUY56289.000291.540 291.286USD 16,312 262.34
2025-05-19BUY48291.860296.800 296.306USD 14,223 261.65
2025-05-16BUY24285.310289.750 289.306USD 6,943 261.46
2025-05-15SELL-16283.400285.000 284.840USD -4,557 261.29 Loss of -377 on sale
2025-05-14BUY8267.550270.000 269.755USD 2,158 261.24
2025-05-13BUY16266.860268.070 267.949USD 4,287 261.19
2025-05-12BUY56270.190270.200 270.199USD 15,131 261.12
2025-05-09SELL-40251.150260.000 259.115USD -10,365 261.20 Profit of 83 on sale
2025-05-08BUY16258.350270.000 268.835USD 4,301 261.23
2025-05-07BUY24276.550277.850 277.720USD 6,665 261.10
2025-05-02BUY888259.390265.000 264.439USD 234,822 260.93
2025-04-30BUY280263.240263.680 263.636USD 73,818 260.96
2025-04-29BUY72257.190260.540 260.205USD 18,735 261.00
2025-04-28BUY56254.850256.570 256.398USD 14,358 261.05
2025-04-25BUY144251.560253.250 253.081USD 36,444 261.14
2025-04-24SELL-168242.610243.690 243.582USD -40,922 261.30 Profit of 2,977 on sale
2025-04-23BUY152241.970248.590 247.928USD 37,685 261.47
2025-04-22BUY64236.750238.630 238.442USD 15,260 261.70
2025-04-17BUY88234.560235.120 235.064USD 20,686 262.48
2025-04-15BUY80230.930242.150 241.028USD 19,282 263.08
2025-04-11BUY128237.770240.000 239.777USD 30,691 263.55
2025-04-09BUY48243.270245.560 245.331USD 11,776 264.12
2025-04-08BUY288224.320246.150 243.967USD 70,262 264.52
2025-04-07BUY96232.950241.830 240.942USD 23,130 264.84
2025-04-04SELL-128235.740259.160 256.818USD -32,873 265.14 Profit of 1,065 on sale
2025-04-02BUY1,088266.830267.290 267.244USD 290,761 265.12
2025-04-01BUY8255.760273.610 271.825USD 2,175 265.22
2025-03-31BUY56270.020271.850 271.667USD 15,213 265.17
2025-03-28BUY32268.460271.300 271.016USD 8,673 265.13
2025-03-27BUY16271.020276.570 276.015USD 4,416 265.07
2025-03-26BUY8269.210281.210 280.010USD 2,240 265.02
2025-03-25BUY88280.960292.620 291.454USD 25,648 264.85
2025-03-24BUY104290.700300.900 299.880USD 31,188 264.56
2025-03-21BUY96283.340289.440 288.830USD 27,728 264.35
2025-03-19BUY24253.440255.350 255.159USD 6,124 264.60
2025-03-18BUY288244.300263.300 261.400USD 75,283 264.83
2025-03-17BUY56253.110253.300 253.281USD 14,184 264.97
2025-03-14BUY416241.760244.040 243.812USD 101,426 265.25
2025-03-13BUY80241.750245.140 244.801USD 19,584 265.53
2025-03-12SELL-400242.430246.370 245.976USD -98,390 265.81 Profit of 7,935 on sale
2025-03-11SELL-296238.740243.450 242.979USD -71,922 266.15 Profit of 6,858 on sale
2025-03-10BUY88233.070244.330 243.204USD 21,402 266.56
2025-03-07BUY16244.520251.120 250.460USD 4,007 266.84
2025-03-05BUY120249.230249.820 249.761USD 29,971 267.07
2025-03-04BUY136242.930244.670 244.496USD 33,251 267.38
2025-03-03BUY256243.530250.000 249.353USD 63,834 267.69
2025-02-28BUY208246.750249.340 249.081USD 51,809 267.97
2025-02-27SELL-40237.100246.380 245.452USD -9,818 268.39 Profit of 917 on sale
2025-02-25BUY296245.200251.560 250.924USD 74,274 269.05
2025-02-21BUY32250.590253.700 253.389USD 8,108 269.60
2025-02-18SELL-72250.000260.000 259.000USD -18,648 270.46 Profit of 825 on sale
2025-02-14SELL-488256.450264.870 264.028USD -128,846 270.89 Profit of 3,348 on sale
2025-02-13BUY8264.890268.520 268.157USD 2,145 270.98
2025-02-12BUY80265.960268.200 267.976USD 21,438 271.06
2025-02-07SELL-8276.190278.030 277.846USD -2,223 270.96 Loss of -55 on sale
2025-02-06BUY152278.250279.240 279.141USD 42,429 270.84
2025-02-05BUY40276.310278.440 278.227USD 11,129 270.74
2025-02-04BUY48271.000277.980 277.282USD 13,310 270.74
2025-02-03BUY48274.550278.510 278.114USD 13,349 270.67
2025-01-31BUY88271.310279.340 278.537USD 24,511 270.66
2025-01-29SELL-8273.990279.700 279.129USD -2,233 270.47 Loss of -69 on sale
2025-01-28SELL-72279.190283.560 283.123USD -20,385 270.31 Loss of -923 on sale
2025-01-27SELL-128276.730287.220 286.171USD -36,630 270.18 Loss of -2,047 on sale
2025-01-24BUY96278.760279.670 279.579USD 26,840 270.01
2025-01-23BUY16275.540277.220 277.052USD 4,433 269.90
2024-12-10BUY400253.910257.990 257.582USD 103,033 270.23
2024-12-09BUY48255.890258.120 257.897USD 12,379 270.53
2024-12-06SELL-120256.260257.810 257.655USD -30,919 270.84 Profit of 1,583 on sale
2024-12-05SELL-8251.810255.290 254.942USD -2,040 271.27 Profit of 131 on sale
2024-12-03BUY40251.840253.210 253.073USD 10,123 272.10
2024-11-27SELL-48253.740256.020 255.792USD -12,278 274.02 Profit of 875 on sale
2024-11-26BUY168253.350253.740 253.701USD 42,622 274.57
2024-11-25BUY1,929250.980255.460 255.012USD 491,918 275.21
2024-11-22SELL-14244.890248.900 248.499USD -3,479 276.05 Profit of 386 on sale
2024-11-21SELL-40246.800250.710 250.319USD -10,013 276.88 Profit of 1,063 on sale
2024-11-20SELL-16248.790249.100 249.069USD -3,985 277.71 Profit of 458 on sale
2024-11-19BUY8234.270235.940 235.773USD 1,886 279.03
2024-11-18BUY72232.270242.490 241.468USD 17,386 280.49
2024-11-11BUY24279.820286.580 285.904USD 6,862 280.89
2024-11-07BUY20272.220275.070 274.785USD 5,496 281.83
2024-11-07BUY20272.220275.070 274.785USD 5,496 281.83
2024-11-06BUY192273.010278.210 277.690USD 53,316 282.56
2024-11-06BUY192273.010278.210 277.690USD 53,316 282.56
2024-11-05BUY40265.290268.890 268.530USD 10,741 284.13
2024-11-05BUY40265.290268.890 268.530USD 10,741 284.13
2024-11-04BUY14269.950272.920 272.623USD 3,817 285.55
2024-11-04BUY14269.950272.920 272.623USD 3,817 285.55
2024-11-01BUY21273.910274.030 274.018USD 5,754 286.84
2024-11-01BUY21273.910274.030 274.018USD 5,754 286.84
2024-10-30SELL-48281.490287.870 287.232USD -13,787 290.50 Profit of 157 on sale
2024-10-30SELL-48281.490287.870 287.232USD -13,787 290.50 Profit of 157 on sale
2024-10-29SELL-144284.690287.020 286.787USD -41,297 291.47 Profit of 674 on sale
2024-10-29SELL-144284.690287.020 286.787USD -41,297 291.47 Profit of 674 on sale
2024-10-28SELL-56286.910290.940 290.537USD -16,270 292.38 Profit of 103 on sale
2024-10-28SELL-56286.910290.940 290.537USD -16,270 292.38 Profit of 103 on sale
2024-10-21SELL-8292.010295.390 295.052USD -2,360 0.00 Loss of -2,360 on sale
2024-10-21SELL-8292.010295.390 295.052USD -2,360 0.00 Loss of -2,360 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19216,7273,259396,24354.7%
2025-09-18172,875397386,43244.7%
2025-09-17246,547167472,29252.2%
2025-09-1688,84660226,33639.3%
2025-09-15148,25813,572435,68934.0%
2025-09-12134,122300244,96854.8%
2025-09-11219,8687,820411,70253.4%
2025-09-10543,3267,595916,89859.3%
2025-09-09705,54033,7311,550,89945.5%
2025-09-08175,158440388,71545.1%
2025-09-05127,116335311,25240.8%
2025-09-04110,9302,555236,56846.9%
2025-09-03182,3868,982562,92132.4%
2025-09-02132,77014,416358,47637.0%
2025-08-2993,2162,181276,59433.7%
2025-08-2860,1821,254226,86526.5%
2025-08-27277,6671,084440,57763.0%
2025-08-26243,404919447,42154.4%
2025-08-25156,55115,662374,27641.8%
2025-08-22228,5961,309408,15256.0%
2025-08-21123,9962,862248,30049.9%
2025-08-20149,63813,723316,98347.2%
2025-08-19144,3201,143308,39946.8%
2025-08-18371,31834,264525,78670.6%
2025-08-15104,01813,245265,62039.2%
2025-08-14133,2724,443505,52826.4%
2025-08-13183,2711,3901,017,62318.0%
2025-08-12173,0454,046693,01825.0%
2025-08-11239,1997,600451,24853.0%
2025-08-08168,7553,199466,74436.2%
2025-08-07308,8104,452527,39958.6%
2025-08-06202,15112,590548,34936.9%
2025-08-05256,29513,237826,28331.0%
2025-08-04411,11436,303729,94956.3%
2025-08-01350,06060,108764,94345.8%
2025-07-31829,1916,0231,541,01553.8%
2025-07-30533,88514,703942,78856.6%
2025-07-29164,26855384,53742.7%
2025-07-28150,24069571,96526.3%
2025-07-2590,782429298,80130.4%
2025-07-24132,00111,546286,15546.1%
2025-07-23184,14963312,34059.0%
2025-07-22134,7617,553524,61225.7%
2025-07-21113,303101243,11946.6%
2025-07-1884,1179196,31742.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.